Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417305 | 1.00 | NPSR1 (0.34) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL5527416 | 0.91 | NPSR1 (0.36) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL14417304 | 0.91 | NPSR1 (0.36) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL9142948 | 0.85 | MEN1 (0.38) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL9095927 | 0.85 | MEN1 (0.38) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL9095923 | 0.85 | MEN1 (0.38) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL7054034 | 0.82 | MEN1 (0.41) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL5528820 | 0.82 | MEN1 (0.41) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL29733864 | 0.82 | MEN1 (0.41) | NPSR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL7176844 | 0.82 | MEN1 (0.41) | NPSR1MEN1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | NPSR1 4427/4885MEN1 1653/4885KMT2A 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.